Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) were up 0% during trading on Thursday following insider buying activity. The company traded as high as $14.42 and last traded at $14.33. Approximately 1,058,755 shares were traded during trading, a decline of 21% from the average daily volume of 1,344,763 shares. The stock had previously closed at $14.33.

Specifically, Director Mara G. Aspinall bought 5,000 shares of the stock in a transaction dated Tuesday, November 7th. The shares were acquired at an average cost of $14.23 per share, for a total transaction of $71,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Douglas A. Michels sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $22.55, for a total transaction of $563,750.00. Following the transaction, the chief executive officer now owns 743,058 shares in the company, valued at $16,755,957.90. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 61,110 shares of company stock worth $1,362,463. Insiders own 6.40% of the company’s stock.

Several equities research analysts recently weighed in on OSUR shares. Canaccord Genuity increased their price target on OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Jefferies Group LLC reaffirmed a “buy” rating and set a $20.00 price target on shares of OraSure Technologies in a report on Tuesday, September 12th. Zacks Investment Research raised OraSure Technologies from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a report on Saturday, September 9th. Finally, BidaskClub downgraded OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $18.21.

The stock has a market cap of $823.51, a price-to-earnings ratio of 26.64, a price-to-earnings-growth ratio of 2.66 and a beta of 1.39.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.09. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The firm had revenue of $42.30 million during the quarter, compared to the consensus estimate of $40.87 million. During the same period last year, the company earned $0.11 earnings per share. The company’s revenue for the quarter was up 31.0% on a year-over-year basis. equities research analysts expect that OraSure Technologies, Inc. will post 0.42 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. First Mercantile Trust Co. acquired a new stake in OraSure Technologies in the second quarter valued at $104,000. Pinebridge Investments L.P. acquired a new stake in OraSure Technologies in the second quarter valued at $131,000. Victory Capital Management Inc. lifted its holdings in OraSure Technologies by 17.6% in the second quarter. Victory Capital Management Inc. now owns 9,070 shares of the medical instruments supplier’s stock valued at $157,000 after acquiring an additional 1,360 shares during the period. Profund Advisors LLC lifted its holdings in OraSure Technologies by 2.8% in the second quarter. Profund Advisors LLC now owns 10,903 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 293 shares during the period. Finally, ETRADE Capital Management LLC acquired a new stake in OraSure Technologies in the second quarter valued at $193,000. 92.56% of the stock is owned by institutional investors.

WARNING: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/09/orasure-technologies-inc-osur-trading-up-0-after-insider-buying-activity.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.